Additionally, the treatment of relapse after blinatumomab use in first line may become more challenging if resistant clones appear earlier on, possibly reducing the potential benefit of CD19‐directed therapies in r/r BCP‐ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.